Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.63 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.57 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5664467 | 0.92 | CA2 (0.60) | CA2HSD11B1PSIP1L3MBTL1MAPT | |
| Dimethylamine SCHEMBL10691829 | 0.92 | CA2 (0.55) | CA2HSD11B1PSIP1L3MBTL1MAPT | |
| SCHEMBL9325260 | 0.87 | CA2 (0.78) | CA2MAPTALDH1A1LMNAKMT2A | |
| Diethylamine SCHEMBL10690280 | 0.87 | PSIP1 (0.53) | CA2HSD11B1PSIP1L3MBTL1MAPT | |
| SCHEMBL7207184 | 0.86 | CA2 (0.66) | CA2HSD11B1PSIP1L3MBTL1MAPT | |
| SCHEMBL777601 | 0.85 | PSIP1 (0.67) | CA2HSD11B1PSIP1L3MBTL1MAPT | |
| SCHEMBL3917294 | 0.85 | CA2 (0.67) | CA2HSD11B1PSIP1L3MBTL1MAPT | |
| SCHEMBL1007970 | 0.83 | CA2 (0.65) | CA2HSD11B1PSIP1L3MBTL1MAPT | |
| SCHEMBL7295500 | 0.83 | CA2 (0.65) | CA2HSD11B1PSIP1L3MBTL1MAPT | |
| SCHEMBL7298810 | 0.83 | CA2 (0.65) | CA2HSD11B1PSIP1L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 355 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025053791-A1 | ONE-POT GRAFTING OF POLYMERS FROM ALCOHOLS AND BIOMASSES | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2025-03-13 | — | — | WO | claimed |
| CN-113631564-B | Method for producing oligonucleotide having phosphorothioate site | 味之素株式会社 | 2025-02-25 | — | — | CN | claimed |
| EP-3015467-B1 | MORPHOLINO OLIGONUCLEOTIDE MANUFACTURING METHOD | AJINOMOTO KK (JP) | 2024-12-04 | — | — | EP | claimed |
| US-20040200993-A1 | Reactive liquid polymer crosslinking agent and process for preparation | LCB WORLDWIDE, INC. | 2004-10-14 | — | — | US | claimed |
| US-20040142946-A1 | Modified nucleosides and nucleotides and use thereof | CHATTOPADHYAYA JYOTI (SE) | 2004-07-22 | — | — | US | claimed |
| US-20030168629-A1 | Reactive liquid polymer crosslinking agent and process for preparation | LCB WORLDWIDE, INC. | 2003-09-11 | — | — | US | claimed |
| EP-1332150-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES AND USE THEREOF | Chattopadhyaya, Jyoti (SE) | 2003-08-06 | — | — | EP | claimed |
| US-20030125329-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-07-03 | — | — | US | claimed |
| US-20030125328-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-07-03 | — | — | US | claimed |
| US-20030119833-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-06-26 | — | — | US | claimed |
| US-20030083331-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-05-01 | — | — | US | claimed |
| US-20030032644-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-02-13 | — | — | US | claimed |
| US-20020165232-A1 | Substituted N, N-disubstituted cycloalkyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2002-11-07 | — | — | US | claimed |
| US-20020165231-A1 | Substituted N-heteroaryl-N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2002-11-07 | — | — | US | claimed |
| WO-2002038578-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES AND USE THEREOF | CHATTOPADHYAYA JYOTI (SE) | 2002-05-16 | — | — | WO | claimed |
| EP-1115693-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | claimed |
| WO-2000018721-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| US-5721350-A | Deuterated nucleosides | CHATTOPADHYAYA JYOTI (SE) | 1998-02-24 | — | — | US | claimed |
| EP-0074763-B1 | A COLOR PHOTOGRAPHIC LIGHT-SENSITIVE MATERIAL | KONICA CORPORATION (JP) | 1986-03-05 | — | — | EP | claimed |
| US-4430424-A | AROMATIC PRIMARY AMINE DEVELOPING AGENT | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1984-02-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125328-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | CA2 4443/4885HSD11B1 844/4885PSIP1 1511/4885 |
| US-20040142946-A1 | Modified nucleosides and nucleotides and use thereof | RNASEH1, RNASEL, NSUN2 | CA2 2368/4885HSD11B1 4090/4885PSIP1 3898/4885 |
| US-20020165231-A1 | Substituted N-heteroaryl-N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, LCAT, MTTP | CA2 4562/4885HSD11B1 617/4885PSIP1 1666/4885 |
| US-20030119833-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | CA2 4443/4885HSD11B1 844/4885PSIP1 1511/4885 |
| US-20030083331-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | CA2 4443/4885HSD11B1 844/4885PSIP1 1511/4885 |
| US-20030032644-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, PCTP | CA2 3853/4885HSD11B1 1085/4885PSIP1 1822/4885 |
| US-20020165232-A1 | Substituted N, N-disubstituted cycloalkyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, PLTP | CA2 4517/4885HSD11B1 614/4885PSIP1 2093/4885 |
| US-20030125329-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | CA2 4443/4885HSD11B1 844/4885PSIP1 1511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.